Silvercrest Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $754K | Hold |
8,338
| – | – | ﹤0.01% | 653 |
|
|
2026
Q1 | $668K | Sell |
8,338
-459
| -5% | -$37.8K | ﹤0.01% | 647 |
|
|
2025
Q4 | $750K | Hold |
8,797
| – | – | 0.01% | 649 |
|
|
2025
Q3 | $684K | Sell |
8,797
-90
| -1% | -$7.03K | ﹤0.01% | 659 |
|
|
2025
Q2 | $695K | Buy |
8,887
+161
| +2% | +$12K | ﹤0.01% | 672 |
|
|
2025
Q1 | $632K | Buy |
8,726
+57
| +0.7% | +$4.08K | ﹤0.01% | 659 |
|
|
2024
Q4 | $642K | Sell |
8,669
-147
| -2% | -$10.3K | ﹤0.01% | 654 |
|
|
2024
Q3 | $582K | Buy |
8,816
+147
| +2% | +$10.7K | ﹤0.01% | 633 |
|
|
2024
Q2 | $801K | Sell |
8,669
-1,687
| -16% | -$149K | 0.01% | 645 |
|
|
2024
Q1 | $990K | Sell |
10,356
-16
| -0.2% | -$1.34K | 0.01% | 615 |
|
|
2023
Q4 | $791K | Sell |
10,372
-379
| -4% | -$26.4K | 0.01% | 616 |
|
|
2023
Q3 | $745K | Hold |
10,751
| – | – | 0.01% | 634 |
|
|
2023
Q2 | $1.01M | Sell |
10,751
-3,242
| -23% | -$282K | 0.01% | 593 |
|
|
2023
Q1 | $1.16M | Sell |
13,993
-18,389
| -57% | -$1.45M | 0.01% | 557 |
|
|
2022
Q4 | $2.42M | Buy |
32,382
+45
| +0.1% | +$3.47K | 0.02% | 444 |
|
|
2022
Q3 | $2.67M | Buy |
32,337
+7,527
| +30% | +$724K | 0.02% | 412 |
|
|
2022
Q2 | $2.36M | Buy |
24,810
+10,726
| +76% | +$1.11M | 0.02% | 444 |
|
|
2022
Q1 | $1.66M | Sell |
14,084
-13
| -0.1% | -$1.46K | 0.01% | 529 |
|
|
2021
Q4 | $1.83M | Buy |
14,097
+750
| +6% | +$87.5K | 0.01% | 498 |
|
|
2021
Q3 | $1.51M | Sell |
13,347
-11,897
| -47% | -$1.36M | 0.01% | 520 |
|
|
2021
Q2 | $2.62M | Sell |
25,244
-2,568
| -9% | -$242K | 0.02% | 463 |
|
|
2021
Q1 | $2.33M | Buy |
27,812
+17,908
| +181% | +$1.51M | 0.02% | 471 |
|
|
2020
Q4 | $903K | Sell |
9,904
-146
| -1% | -$12.1K | 0.01% | 547 |
|
|
2020
Q3 | $802K | Hold |
10,050
| – | – | 0.01% | 537 |
|
|
2020
Q2 | $695K | Hold |
10,050
| – | – | 0.01% | 558 |
|
|
2020
Q1 | $632K | Sell |
10,050
-120
| -1% | -$8.65K | 0.01% | 543 |
|
|
2019
Q4 | $791K | Buy |
10,170
+420
| +4% | +$32.8K | 0.01% | 552 |
|
|
2019
Q3 | $715K | Sell |
9,750
-300
| -3% | -$21.1K | 0.01% | 560 |
|
|
2019
Q2 | $619K | Buy |
10,050
+252
| +3% | +$15.2K | 0.01% | 418 |
|
|
2019
Q1 | $625K | Buy |
9,798
+600
| +7% | +$34.2K | 0.01% | 411 |
|
|
2018
Q4 | $470K | Hold |
9,198
| – | – | 0.01% | 402 |
|
|
2018
Q3 | $533K | Sell |
9,198
-1,815
| -16% | -$88.8K | ﹤0.01% | 405 |
|
|
2018
Q2 | $534K | Sell |
11,013
-1,950
| -15% | -$91K | 0.01% | 408 |
|
|
2018
Q1 | $603K | Sell |
12,963
-2,850
| -18% | -$124K | 0.01% | 401 |
|
|
2017
Q4 | $594K | Buy |
+15,813
| New | +$580K | 0.01% | 403 |
|
|
2016
Q3 | – | Sell |
-6,930
| Closed | -$231K | – | 540 |
|
|
2016
Q2 | $231K | Hold |
6,930
| – | – | ﹤0.01% | 504 |
|
|
2016
Q1 | $204K | Buy |
+6,930
| New | +$191K | ﹤0.01% | 516 |
|
Other funds holding EW
Silvercrest Asset Management's EW Position: Q2 2026 in Review
Silvercrest Asset Management held its Edwards Lifesciences (EW) position steady in Q2 2026 at 8,338 shares worth $754K. The position accounts for ﹤0.01% of the portfolio, ranked #653.
Silvercrest Asset Management first reported a position in EW in Q1 2016 and has held it in 37 quarters since. The position peaked at $2.67M in Q3 2022. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Silvercrest Asset Management held 8,338 shares of Edwards Lifesciences worth $754K as of Q2 2026.
- Silvercrest Asset Management left its Edwards Lifesciences share count unchanged in Q2 2026.
- Edwards Lifesciences made up ﹤0.01% of Silvercrest Asset Management's portfolio in Q2 2026, its #653 holding.
- Silvercrest Asset Management first reported a position in Edwards Lifesciences in Q1 2016 and has held it in 37 quarters since.
- Silvercrest Asset Management's Edwards Lifesciences position peaked at $2.67M in Q3 2022.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.